Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestech gets Mexican screening deal:

This article was originally published in Clinica

Executive Summary

California firm Cholestech has won a contract from the Mexican government to conduct cholesterol screening of all workers that operate public transport. The agreement is to supply the communications and transport ministry with the Cholestech LDX system - initially 42 units. This will be done through the company's Mexico City-based distributor, Nutritional Science and Technology (NST). The Mexican government decided on the LDX after the success of a six-month pilot. The system can test at point-of-care for cholesterol, blood glucose, liver enzymes, ALT and AST, and high-sensitivity C-reactive protein. Mexico performs comprehensive healthcare screening of more than 100,000 transport workers per year. The Hayward, California company says it is in discussions with other government departments to expand the programme.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel